MAP2K7 and cancer: To further explore the cisplatin resistance mechanism mediated by GR C622, we assessed cell viability, cisplatin uptake, cisplatin-induced DNA damage, and MEK-ERK activity in cancer cells bearing GR WT or C622A mutant treated with increasing concentrations of cisplatin.